Emerging therapies for alopecia areata
In this medfyle
Expert commentary by Anna Waśkiel-Burnat, MD, PhD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the EADV Virtual Congress and presented by:
Antonella Tosti, MD
Miller School of Medicine, University of Miami
Miami, USA
The content is produced by Infomedica, the official reporting partner of EADV Virtual Congress. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Prof. Brigitte Dréno, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Anna Waśkiel-Burnat, MD, PhD
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
About the Expert
Anna Waśkiel-Burnat, MD, PhD
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
Anna Waśkiel-Burnat is a doctor at the Department of Dermatovenerology, Medical University of Warsaw. She has authored and co-authored many articles and book chapters. Her main scientific interests are hair disorders, especially trichoscopy. Anna Waśkiel-Burnat was invited speaker at numerous dermatology meetings, including 28th and 29th EADV Congress and 1st World Congress of Trichoscopy. She was also reviewer for scientific journals such as Journal of the European Academy of Dermatology and Venereology, Dermatology Review and Dermatologic Therapy. She is a member of the European Academy of Dermatology and Venereology, International Dermocopy Society and International Trichoscopy Society.
References
1. Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019;33(5):850–6.
2. Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol 2019;S0190-9622(19)32688-X.
3. Fetter T, Rios GC, Niebel D, et al. Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the Janus kinase inhibitor ruxolitinib. Acta Derm Venereol 2020;100(10):adv00144.
4. Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical janus kinase inhibitor for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol 2017;78(2):403–4.e1.
5. Bayart CB, DeNiro KL, Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 2017;77(1):167–70.
6. Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol 2018;78(6):1207–9.
7. Craiglow BG. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. JAAD Case Rep 2018;4(10):988–9.
8. Ferreira SB, Ferreira RB, Scheinberg MA. Topical tofacitinib in treatment of alopecia areata. Einstein (Sao Paulo) 2020;18:eA15452.
9. Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf 2018;17(11):1115–28.
10. Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. Lancet 2019;393(10169):318–9.
11. Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of SARS-CoV-2. J Am Acad Dermatol 2020;82(6):e223–6.
